Danaher EBITDA 2010-2025 | DHR
Danaher annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Danaher EBITDA for the quarter ending March 31, 2025 was $1.865B, a 3.02% decline year-over-year.
- Danaher EBITDA for the twelve months ending March 31, 2025 was $7.182B, a 0.9% decline year-over-year.
- Danaher 2024 annual EBITDA was $7.24B, a 1.84% decline from 2023.
- Danaher 2023 annual EBITDA was $7.376B, a 23.71% decline from 2022.
- Danaher 2022 annual EBITDA was $9.668B, a 13.77% increase from 2021.
| Danaher Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $7,240 |
| 2023 | $7,376 |
| 2022 | $9,668 |
| 2021 | $8,498 |
| 2020 | $6,463 |
| 2019 | $4,458 |
| 2018 | $4,233 |
| 2017 | $3,689 |
| 2016 | $3,863 |
| 2015 | $3,043 |
| 2014 | $2,763 |
| 2013 | $3,971 |
| 2012 | $4,005 |
| 2011 | $3,252 |
| 2010 | $2,438 |
| 2009 | $1,771 |
| Danaher Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-03-31 | $1,865 |
| 2024-12-31 | $2,020 |
| 2024-09-30 | $1,549 |
| 2024-06-30 | $1,748 |
| 2024-03-31 | $1,923 |
| 2023-12-31 | $1,903 |
| 2023-09-30 | $1,718 |
| 2023-06-30 | $1,703 |
| 2023-03-31 | $2,052 |
| 2022-12-31 | $1,619 |
| 2022-09-30 | $2,555 |
| 2022-06-30 | $2,757 |
| 2022-03-31 | $2,737 |
| 2021-12-31 | $1,560 |
| 2021-09-30 | $1,880 |
| 2021-06-30 | $2,530 |
| 2021-03-31 | $2,528 |
| 2020-12-31 | $2,149 |
| 2020-09-30 | $1,800 |
| 2020-06-30 | $1,519 |
| 2020-03-31 | $995 |
| 2019-12-31 | $1,261 |
| 2019-09-30 | $1,072 |
| 2019-06-30 | $1,110 |
| 2019-03-31 | $1,016 |
| 2018-12-31 | $815 |
| 2018-09-30 | $1,152 |
| 2018-06-30 | $1,202 |
| 2018-03-31 | $1,064 |
| 2017-12-31 | $716 |
| 2017-09-30 | $1,071 |
| 2017-06-30 | $980 |
| 2017-03-31 | $923 |
| 2016-12-31 | $1,019 |
| 2016-09-30 | $976 |
| 2016-06-30 | $988 |
| 2016-03-31 | $881 |
| 2015-12-31 | $265 |
| 2015-09-30 | $616 |
| 2015-06-30 | $1,171 |
| 2015-03-31 | $991 |
| 2014-12-31 | $941 |
| 2014-09-30 | $1,071 |
| 2014-06-30 | $1,125 |
| 2014-03-31 | $1,014 |
| 2013-12-31 | $1,077 |
| 2013-09-30 | $1,038 |
| 2013-06-30 | $1,063 |
| 2013-03-31 | $948 |
| 2012-12-31 | $1,083 |
| 2012-09-30 | $966 |
| 2012-06-30 | $1,019 |
| 2012-03-31 | $937 |
| 2011-12-31 | $983 |
| 2011-09-30 | $851 |
| 2011-06-30 | $729 |
| 2011-03-31 | $689 |
| 2010-12-31 | $659 |
| 2010-09-30 | $649 |
| 2010-06-30 | $615 |
| 2010-03-31 | $515 |
| 2009-12-31 | $370 |
| 2009-09-30 | $550 |
| 2009-06-30 | $430 |
| 2009-03-31 | $421 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $146.605B | $23.875B |
| Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVS Health (CVS) | United States | $81.948B | 10.19 |
| Elevance Health (ELV) | United States | $76.969B | 9.93 |
| Cencora (COR) | United States | $57.219B | 19.91 |
| DiDi Global (DIDIY) | China | $24.191B | 25.70 |
| Natera (NTRA) | United States | $21.906B | 0.00 |
| Labcorp Holdings (LH) | United States | $20.893B | 16.95 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.687B | 0.00 |
| CochLear (CHEOY) | Australia | $12.827B | 0.00 |
| Solventum (SOLV) | United States | $12.768B | 13.52 |
| ICON (ICLR) | Ireland | $12.156B | 11.30 |
| Revvity (RVTY) | United States | $11.964B | 20.59 |
| Viatris (VTRS) | United States | $10.704B | 3.68 |
| Medpace Holdings (MEDP) | United States | $9.298B | 24.69 |
| Avantor (AVTR) | United States | $9.254B | 13.45 |
| Sonic Healthcare (SKHHY) | Australia | $8.886B | 0.00 |
| HealthEquity (HQY) | United States | $8.174B | 35.80 |
| Charles River Laboratories (CRL) | United States | $7.829B | 15.34 |
| Caris Life Sciences,�Inc (CAI) | United States | $6.744B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.911B | 28.92 |
| BrightSpring Health Services (BTSG) | United States | $3.571B | 32.76 |
| Sotera Health (SHC) | United States | $3.349B | 19.03 |
| Surgery Partners (SGRY) | United States | $2.825B | 36.73 |
| Alignment Healthcare (ALHC) | United States | $2.645B | 0.00 |
| Organon (OGN) | United States | $2.584B | 2.75 |
| Concentras Parent (CON) | United States | $2.551B | 14.74 |
| GeneDx Holdings (WGS) | United States | $2.356B | 90.72 |
| Ardent Health (ARDT) | United States | $2.027B | 8.64 |
| Progyny (PGNY) | United States | $1.990B | 43.79 |
| PACS (PACS) | United States | $1.932B | 0.00 |
| Premier (PINC) | United States | $1.736B | 13.18 |
| GoodRx Holdings (GDRX) | United States | $1.695B | 33.89 |
| Teladoc Health (TDOC) | United States | $1.460B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.298B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.127B | 8.58 |
| CareDx (CDNA) | United States | $1.121B | 17.50 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.923B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 291.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.810B | 7.58 |
| Nutex Health (NUTX) | United States | $0.637B | 9.64 |
| Embecta (EMBC) | United States | $0.612B | 4.12 |
| InnovAge Holding (INNV) | United States | $0.559B | 0.00 |
| SBC Medicals (SBC) | United States | $0.523B | 0.00 |
| LifeMD (LFMD) | United States | $0.512B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.482B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.471B | 10.60 |
| Omada Health (OMDA) | $0.455B | 0.00 | |
| So-Young (SY) | China | $0.390B | 0.00 |
| Enhabit (EHAB) | United States | $0.357B | 29.38 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.344B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.321B | 0.00 |
| Oncology Institute (TOI) | United States | $0.279B | 0.00 |
| Beauty Health (SKIN) | United States | $0.241B | 0.00 |
| DocGo (DCGO) | United States | $0.152B | 24.83 |
| Pheton Holdings (PTHL) | China | $0.138B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.107B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.079B | 0.00 |
| KindlyMD (NAKA) | United States | $0.074B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.061B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| ModivCare (MODV) | United States | $0.046B | 0.00 |
| Biodesix (BDSX) | United States | $0.045B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.023B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |